Charcot-Marie-Tooth Disease - 7MM Market Insights, Epidemiology, and Market Forecast - 2036 | Precision Therapies and Genetic Diagnostics Unlock Growth Opportunities
Dublin, Oct. 15, 2026 (GLOBE NEWSWIRE) -- "Charcot-Marie-Tooth Disease - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The Charcot-Marie-Tooth (CMT) disease market is entering a period of significant clinical and commercial development, driven by advances in genetic testing, improved disease subtype identification, and an expanding pipeline of targeted therapies. The report provides comprehensive analysis of CMT disease epidemiology, treatment practices, pipeline development, market access, and forecast trends across the United States, EU4 countries - Germany, Spain, Italy, and France - the United Kingdom, and Japan.
CMT disease is among the most common inherited neuromuscular disorders, affecting an estimated 2.6-3 million people worldwide. Epidemiological studies indicate a prevalence of approximately 1 in 2,500 people in the United States and Europe, although reported rates vary by geography and diagnostic methodology. In Japan, prevalence is estimated at approximately 1 in 10,000 people. The actual patient population may be higher because of delayed diagnosis, incomplete genetic testing, and the clinical complexity of less common subtypes.
More than 100 genes have been associated with CMT disease, with PMP22, MPZ, GJB1, and MFN2 among the most frequently implicated. CMT1A, associated with duplication of the PMP22 gene, represents approximately 60-70% of CMT disease cases. The growing adoption of next-generation sequencing, molecular diagnostics, Nerve Conduction Studies (NCS), and electromyography (EMG) is improving diagnostic accuracy, supporting subtype classification, and enabling more precise enrollment in clinical trials.
Current Treatment Landscape and Unmet Medical Need
There are currently no FDA-approved disease-modifying therapies for CMT disease. Management remains focused on physical therapy, occupational therapy, muscle strengthening, stretching, orthopedic support, shoe orthotics, leg braces, corrective surgery, and pharmacological management of neuropathic pain and musculoskeletal discomfort. Treatment is individualized according to genetic subtype, functional impairment, disease severity, and progression.
Major unmet needs include the absence of curative or disease-modifying therapies, delayed genetic diagnosis, progressive disability despite supportive treatment, and limited targeted options for genetically diverse patient populations. These challenges can substantially affect mobility, quality of life, and long-term functional independence, creating a strong need for therapies capable of slowing peripheral nerve degeneration or improving neuromuscular function.
Pipeline Innovation Reshapes the CMT Disease Market
The emerging CMT disease pipeline includes siRNA therapies, Antisense Oligonucleotides (ASOs), HDAC6 inhibitors, gene therapies, neuromuscular modulators, and other precision medicine approaches. These programs are designed to address pathogenic gene overexpression, axonal degeneration, peripheral nerve dysfunction, and impaired skeletal muscle activation.
Key investigational assets include ignaseclant (NMDP-08) from NMD Pharma, EDK060 from Novartis, ABS-0871 from Actio Biosciences, VCA-894A, AGT-100216, and govorestat from Applied Therapeutics. Several development programs have received orphan drug incentives, reflecting the considerable unmet medical need and limited availability of effective pharmacological options.
Govorestat is being developed for CMT-SORD and has received Orphan Medicinal Product Designation from the European Medicines Agency and Orphan Drug Designation from the FDA. Ignaseclant, also identified as NMDP-08/NMD670, is an investigational first-in-class inhibitor of the skeletal muscle specific Chloride Ion Channel 1 (ClC-1). The therapy has been evaluated in the Phase IIa SYNAPSE-CMT study involving patients with CMT types 1 or 2.
Market Growth Drivers and Commercial Outlook
The CMT disease therapeutics market is expected to evolve from a supportive care based model toward genetically targeted and disease-modifying treatment. Growth will be supported by increased rare disease awareness, broader access to molecular diagnostics, orphan drug incentives, clinical trial activity, and investment in inherited neuromuscular disorders.
The United States is expected to remain a major market because of its established rare disease development ecosystem, access to advanced genetic testing, and favorable incentives for orphan therapies. Across the 7MM, market expansion will also depend on regulatory approvals, treatment pricing, reimbursement decisions, demonstrated long-term safety, and evidence that emerging therapies can preserve motor function or slow disease progression.
Uptake of supportive and rehabilitative interventions is expected to remain stable because these services continue to form the foundation of CMT disease management. Adoption of emerging precision therapies is likely to occur gradually and will be influenced by genetic eligibility, efficacy, route and frequency of administration, payer coverage, physician acceptance, and real-world outcomes. Therapies addressing well-defined genetic subtypes may achieve earlier adoption where diagnostic pathways and patient identification are established.
Competitive Intelligence and Strategic Market Assessment
The report evaluates clinical development, therapy uptake, peak patient share, revenue potential, pricing trends, reimbursement, and competitive positioning during the 2022-2036 period. It also reviews key companies, including NMD Pharma, Novartis, Actio Biosciences, Vanda Pharmaceuticals, Augustine Therapeutics, and ENCell.
Primary research incorporates perspectives from more than 10 Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs), including clinicians, researchers, professors, and other specialists. These insights help validate epidemiological assumptions, treatment patterns, accessibility barriers, patient adherence, therapy switching, and anticipated adoption of emerging CMT disease treatments.
SWOT and conjoint analyses assess competitive strengths, development risks, diagnostic challenges, geographical accessibility, and treatment attributes such as safety, efficacy, administration frequency, route of administration, probability of success, order of market entry, and addressable patient population. This evidence supports market forecasting, pipeline prioritization, product positioning, and launch strategy development.
Key Report Insights
The report offers actionable intelligence for pharmaceutical companies, investors, healthcare providers, and other stakeholders evaluating opportunities in the Charcot-Marie-Tooth disease market. By integrating epidemiology-based forecasting, clinical pipeline analysis, expert perspectives, and market access considerations, it supports informed decisions related to research investment, competitive strategy, therapy development, and commercialization across major global markets.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
4.1. Upcoming Key Catalysts
4.2. Key Conferences And Meetings
4.3. Key Transactions And Collaborations
4.4. News Flow
5. Epidemiology and Market Methodology of Charcot-Marie-Tooth (CMT) Disease
6. Charcot-Marie-Tooth (CMT) Disease Market Overview at a Glance
6.1. Emerging Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2. Market Share of CMT Disease By Therapies (%) in the 7MM in 2028
6.3. Market Share of CMT Disease By Therapies (%) in the 7MM in 2036
7. Disease Background And Overview of Charcot-Marie-Tooth (CMT) Disease
7.1. Introduction
7.2. Causes
7.3. Diagnosis
7.3.1. Diagnostic Guidelines
7.3.2. Diagnostic Algorithm
8. Treatment and Management
8.1. Treatment Guidelines
8.2. Treatment Algorithm
9. Epidemiology and Patient Population of Charcot-Marie-Tooth (CMT) Disease
9.1. Key Findings
9.2. Assumptions and Rationale: The 7MM
9.3. Total Diagnosed Prevalent Cases of CMT Disease in the 7MM
9.4. The United States
9.4.1. Total Prevalent Cases of CMT Disease in the United States
9.4.2. Total Diagnosed Prevalent Cases of CMT Disease in the United States
9.4.3. Gender-specific Diagnosed Prevalent Cases of CMT Disease in the United States
9.4.4. Type-specific Diagnosed Prevalent Cases of CMT Disease in the United States
9.4.5. Age-specific Diagnosed Prevalent Cases of CMT Disease in the United States
9.4.6. Total treated cases of CMT Disease in the United States
9.5. EU4 and the UK
9.5.1. Total Prevalent Cases of CMT Disease in EU and the UK
9.5.2. Total Diagnosed Prevalent Cases of CMT Disease in EU and the UK
9.5.3. Gender-specific Diagnosed Prevalent Cases of CMT Disease in EU and the UK
9.5.4. Type-specific Diagnosed Prevalent Cases of CMT Disease in EU and the UK
9.5.5. Age-specific Diagnosed Prevalent Cases of CMT Disease in EU and the UK
9.5.6. Total treated cases of CMT Disease in EU and the UK
9.6. Japan
9.6.1. Total Prevalent Cases of CMT Disease in Japan
9.6.2. Total Diagnosed Prevalent Cases of CMT Disease in Japan
9.6.3. Gender-specific Diagnosed Prevalent Cases of CMT Disease in Japan
9.6.4. Type-specific Diagnosed Prevalent Cases of CMT Disease in Japan
9.6.5. Age-specific Diagnosed Prevalent Cases of CMT Disease in Japan
9.6.6. Total treated cases of CMT Disease in Japan
10. Patient Journey of Charcot-Marie-Tooth (CMT) Disease
11. Emerging Therapies
11.1. Competitive Landscape: Emerging Therapies
11.2. Ignaseclant (NMDP-08): NMD Pharma
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Analyst's View
11.3. ABS-0871: Actiobiosciences
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.4. Safety and Efficacy
11.3.5. Analyst's View
12. Charcot-Marie-Tooth (CMT) Disease: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Outlook
12.3. Conjoint Analysis
12.4. Key Market Forecast Assumptions
12.5. Total Market Size of CMT Disease in the 7MM
12.6. Total Market Size of CMT Disease by Therapies in 7MM
12.7. The United States Market Size
12.7.1. Total Market Size of CMT Disease in the United States
12.7.2. Total Market Size of CMT Disease by Current SOC in the United States
12.7.3. Total Market Size of CMT Disease by Emerging Therapies in the United States
12.8. EU4 and the UK Market Size
12.8.1. Total Market Size of CMT Disease in EU4 and the UK
12.8.2. Total Market Size of CMT Disease by Current SOC in EU4 and the UK
12.8.3. Total Market Size of CMT Disease by Emerging Therapies in EU4 and the UK
12.9. Japan Market Size
12.9.1. Total Market Size of CMT Disease in Japan
12.9.2. Total Market Size of CMT Disease by Current SOC in Japan
12.9.3. Total Market Size of CMT Disease by Emerging Therapies in Japan
13. Unmet Needs of Charcot-Marie-Tooth (CMT) Disease
14. SWOT Analysis of Charcot-Marie-Tooth (CMT) Disease
15. KOL Views of Charcot-Marie-Tooth (CMT) Disease
15.1. Expert/KOL Interview Highlights
16. Market Access and Reimbursement of Charcot-Marie-Tooth (CMT) Disease
16.1. United States
16.1.1. Centre for Medicare and Medicaid Services (CMS)
16.2. EU4 and the UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. United Kingdom
16.3. Japan
16.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
17. Appendix
17.1. Bibliography
17.2. Report Methodology
18. Analyst's Capabilities
19. Disclaimer
20. About the Publisher
List of Tables [35]
List of Figures [35]
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/zao0dj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.